<DOC>
	<DOCNO>NCT00819403</DOCNO>
	<brief_summary>To determine whether combination ezetimibe simvastatin improve biomarkers atherothrombosis compare simvastatin alone patient metabolic syndrome .</brief_summary>
	<brief_title>Simvastatin With Without Ezetimibe Atherothrombotic Biomarker Assessment</brief_title>
	<detailed_description>1 . To assess ex vivo effect ezetimibe/simvastatin ( E/S ) ( Vytorin 10/40mg ) simvastatin ( S ) ( Zocor 40mg ) platelet inflammation biomarkers patient document metabolic syndrome . 2 . To compare platelet-related effect include PAR-1 receptor inhibition E/S establish anti-platelet agent include aspirin , clopidogrel , intravenous oral glycoprotein IIb/IIIa inhibitor . 3 . To determine whether addition ezetimibe yield extra protection beyond lipid modulation reduction inflammation platelet activation .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>1 . Men woman great equal 21 year age 2 . Diagnosis metabolic syndrome . We define presence metabolic syndrome base US National Cholesterol Education Program 's Adult Treatment Panel III guideline . Specifically , metabolic syndrome diagnose documented 3 follow 5 characteristic present : abdominal obesity , give waist circumference men &gt; 102 cm , woman &gt; 88 cm triglyceride &gt; 150 mg/dL HDL cholesterol &lt; 40 mg/dL men , &lt; 50 mg/dL woman blood pressure &gt; 130/85 mm Hg fast glucose &gt; 100 mg/dL 1 . Patients exclude history bleed diathesis 2. drug alcohol abuse 3. prothrombin time great 1.5 time control 4. platelet count &lt; 100,000/mm3 5. hematocrit &lt; 25 % 6. creatinine &gt; 4.0 mg/dl 7. surgery angioplasty perform within 3 month plan future 8. history gastrointestinal bleeding 9. history druginduced disorder 10. trauma , cancer , rheumatic disease , coronary artery disease stroke 11 . Patients participate investigational drug trial within one month completion also exclude 12 . Patients treat intravenous platelet glycoprotein IIb/IIIa inhibitor thienopyridines , within past 6 month 13 . Patients treat statin aspirin within past four week</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>triglyceride</keyword>
	<keyword>hypertension</keyword>
	<keyword>low hdl</keyword>
	<keyword>obesity</keyword>
</DOC>